Intuitive Surgical (ISRG) is back in focus after a recent analyst upgrade, along with fresh data points on profitability, procedure volumes, recurring revenue and adoption of its latest da Vinci 5 platform.

The recent analyst upgrade and strong Q1 profitability come as the stock trades at US$426.61, with the share price down 24.09% year to date but supported by a 35.24% three year total shareholder return. This suggests longer term holders have still seen gains even as shorter term momentum has cooled.

If you are interested in how robotic surgery and automation trends extend beyond a single stock, this is a good moment to see what else is out there with the 33 robotics and automation stocks

With the stock down 24.09% year to date, but supported by a 35.24% three year total return and analyst optimism around earnings, you now have to ask: is Intuitive Surgical undervalued, or is the market already pricing in future growth?

Most Popular Narrative: 19.9% Undervalued

According to the most followed narrative, Intuitive Surgical's fair value sits at $532.46 compared with the last close at $426.61, which frames the current discount as meaningful in that model.

Update on Valuation (18.10.26) Over the next 5 years I calculate with (actual values from 18.01.26, price/shr at 533 USD): Revenue Growth p.a.: 12% (Currently at 14,7%). We saw the peak of revenue growth with nearly 15%. Now even 12% is sporty, but with the "subscription-like" revenues from spare parts and software licences, based on a still growing base of installed systems, this appears realistic. Profit Margin: 30% (currently at 28,6%) because spare parts in general have more margin than system sales, and the sales out of spare parts are still growing. Future PE: 50 (currently at 69). The high PEs are typical for fast growers, but over time the PE may go down; I see for the next 5 years 50, and in 10 years it could come down to 40. Interest rate: 6,77% (same as current). This leads to an FV of 533 USD, meaning ISRG trades within 0,5% of fair value. I calculate the internal rate of return (IRR) of an investment at the current stock price over a period of 5 years. At the current value I get 6,8% annual return on share price. This is below my expectation of 10%. But ISRG is always very expensive, and if the price further drops to 480 USD, you would reach 9% annual return. This is below my expectation of 10%.

Curious how this fair value hangs together? The narrative leans on sustained double digit revenue growth, thicker margins from recurring sales, and a premium future earnings multiple. The exact mix of these assumptions is what drives that $532.46 figure, and it is more nuanced than a simple one line DCF or headline P/E suggests.

Result: Fair Value of $532.46 (UNDERVALUED)

However, this fair value story could be pressured if procedure volumes slow or if hospitals delay adoption of the da Vinci 5 system, which would affect recurring revenue assumptions.

Another View: Multiples Point To A Rich Price

The popular fair value narrative describes Intuitive Surgical as about 19.9% undervalued at $532.46. However, the current P/E of 50.7x tells a tougher story. It sits well above the US Medical Equipment industry at 25.4x, the peer average at 26x, and a fair ratio of 31.3x.

That kind of premium suggests the stock price already reflects a lot of future success. This raises a simple question for you as an investor: how comfortable are you paying well above both the sector and that fair ratio for the current growth profile?

Next Steps

With sentiment mixed between undervalued potential and a rich P/E, this is the moment to move fast and weigh the trade off for yourself. To see what others are optimistic about, review the stock's 3 key rewards

Looking for more investment ideas?

If you stop with just one stock, you might miss other opportunities that fit your style, so use the Simply Wall St Screener to widen your field of options.

• Spot potential bargains early by scanning screener containing 21 high quality undiscovered gems that pair quality fundamentals with relatively low market attention.
• Strengthen your core holdings by reviewing companies in the solid balance sheet and fundamentals stocks screener (46 results) that may offer stronger financial footing.
• Reduce portfolio stress by checking out 63 resilient stocks with low risk scores focused on companies with lower risk scores and steadier profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.